Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423713 | 0.90 | ALOX5AP (0.46) | PPARGCCR2ALOX5AP | |
| SCHEMBL7422217 | 0.89 | CCR2 (0.46) | CCR2ALOX5APNPC1CASP3RAB9A | |
| SCHEMBL7422231 | 0.88 | MAPT (0.47) | PPARGNPC1RAB9APTGES | |
| SCHEMBL7425963 | 0.86 | AGTR1 (0.51) | PPARGAGTR1AGTR2SMN1; SMN2 | |
| SCHEMBL5882169 | 0.83 | CCR2 (0.50) | PPARGCCR2ALOX5APSLC22A12NPC1 | |
| SCHEMBL6170375 | 0.80 | AGTR1 (0.62) | PPARGAGTR1AGTR2PTGES | |
| SCHEMBL7425637 | 0.79 | MAPT (0.48) | PPARGCCR2NPC1RAB9A | |
| SCHEMBL5882472 | 0.78 | LMNA (0.46) | PPARGCCR2NPC1SMN1; SMN2 | |
| SCHEMBL8006723 | 0.78 | MAPT (0.44) | PPARGCCR2ALOX5APNPC1RAB9A | |
| SCHEMBL7419326 | 0.78 | SLC22A12 (0.45) | CCR2ALOX5APSLC22A12PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624893-A2 | INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY | Applied Research Systems ARS Holding N.V. (AN) | 2006-02-15 | — | — | EP | claimed |
| WO-2004087211-A2 | INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-10-14 | — | — | WO | claimed |
| EP-1877399-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| EP-1673355-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | Pfizer Limited (GB) | 2006-06-28 | — | — | EP | disclosed |
| EP-1572173-A1 | ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1562602-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005028452-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004054560-A1 | ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004037262-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-6358992-B1 | Method of inhibiting neoplastic cells with indole derivatives | CELL PATHWAYS, INC. | 2002-03-19 | — | — | US | disclosed |
| US-6069156-A | Indole derivatives as cGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-30 | — | — | US | disclosed |
| EP-0820441-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032379-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-17 | — | — | WO | disclosed |